PULMONARY FUNCTION TEST CHANGES BY AYURVEDIC TREATMENT IN TAMAKA SHVASA (BRONCHIAL ASTHMA): A RANDOMIZED CONTROLLED CLINICAL TRIAL

Abstract

Background- Asthma is a chronic lung disease affecting people of all ages. It is caused by inflammation and muscles tightening around the airways in lungs which can be any combination of coughing, wheezing, shortness of breath and chest tightness. Asthma affects an estimated 262 million people in 2019 and caused 455000 deaths.

Objective: The study design to evaluate the effect of “Simhyadi Kwath” in comparison with Tablet Doxofylline on Bronchial Asthma by Pulmonary Function Test.

Methods- In the open label randomized controlled clinical trial 30 patients in trial group was treated with Simhyadi Kwath for 45 days and 30 patients in control group was managed by tablet Doxofylline for 45 days. Assessment was done on the basis of Pulmonary Function Test by spirometer, PEFR and SMI.

Result- Simhyadi Kwath is better to increase FEV1, FVC, FEV 25-75, PEFR and SMI than the tablet Doxofylline by considering mean difference. Simhyadi Kwath is significant in treatment of Tamaka Shvasa with increases FEV1 by 20.733±6.628 (t-17.134 & P<0.0001), FVC by 15.633±6.825 (t-12.546& P<0.0001), FEV 25-75 by 35.033±18.891 (t- 10.158 & P<0.0001), PEFR by 109.53±31.065 (t- 19.277 & P<0.0001), SMI by -2.033±0.9279 (t-12.003 & P<0.0001) and reduces lung age by 19.90±8.531 (t-12.77 & P<0.0001). Tablet Doxofylline improves PFT parameter with increasing FEV1 by  17.667±8.185 (t-18.823 & P<0.0001), FVC by 15.167±7.264 (t-11.436 & P<0.0001), FEV 25-75 by -26.767±21.66 (t-6.767 & P<0.0001), PEFR by -85.33±31.154 (t- 15.003 & P<0.0001), SMI by-1.533±0.7303 (t- 19.277 & P<0.0001) and lung age by 16.467±10.817 (t- 8.338 & P<0.0001).

Discussion and Conclusion- The comparative study showed that Ayurvedic Simhyadi Kwath was more effective in treatment of Tamaka Shvasa with improvement in PFT parameters without side effects.